Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Brief Description  
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of MK-5172 when administered with peg-interferon alfa-2b and Ribavirin in treatment naive genotype 1 hepatitis C infected patients. All study patients will receive triple therapy treatment.
Who may be Eligible  
Adult men and women 18 years of age and older with genotype 1 chronic Hepatitis C infection that have not received prior treatment. Participants may not have cirrhosis of the liver.
IRB Number  
Principal Investigator  
Russo, Mark

For More Information, Contact  Regina  , McFadden
Phone:  (704) 355-7608  Fax:  (704) 355-9641  
Email:  regina.mcfadden@carolinashealthcare.org
Address:1300 Scott Avenue Charlotte, NC